Description of Compensation Arrangement with respect to Named Executive Officers
Contract Categories:
Human Resources
- Compensation Agreements
EX-10.27 7 b405388_ex10-27.htm DESCRIPTION OF COMPENSATION Prepared and filed by St Ives Burrups
Exhibit 10.27
Description of Compensation Arrangement with respect to Named Executive Officers
The following sets forth the annual rate at which the specified named executive officers (as defined in Regulation S-K Item 402(a)(3)) will be paid in 2005 and the cash bonus each was awarded for the fiscal year 2004 as approved by the Compensation Committee of the Board of Directors of Progenics Pharmaceuticals, Inc.
| Name | Title | 2005 Salary | Cash Bonus |
| Paul J. Maddon, M.D., Ph.D. | Chief Executive Officer and Chief Science Officer | $536,785 | $150,000 |
| Robert J. Israel, M.D. | Senior Vice President, Medical Affairs | 312,000 | 50,000 |
| Robert A. McKinney | Chief Financial Officer, Vice President, Finance and Operations and Treasurer | 230,000 | 60,000 |
| Ronald J. Prentki(1) | President and Director | 385,650 | 75,000 |
(1) Mr. Prentki notified the Registrant of his resignation, effective March 25, 2005, as President of the Registrant.
